Medicine for treating upper respiratory tract infection and its prepn

A technology for the upper respiratory tract and drugs, applied in drug combinations, medical formulas, respiratory diseases, etc., can solve the problems of not having the dual effects of anti-virus and bacteria of traditional Chinese medicine, complicated and impure drugs, and limited drug range, so as to improve the local tissue Effects of cell ischemia, pain relief, and low production cost

Active Publication Date: 2007-11-14
安徽济人药业股份有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the currently developed products either do not have the dual anti-virus and bacterial effects of traditional Chinese medicine, or have used bitter and cold products such as Lianqin, which are not consistent with the pathogenesis of lung health at the beginning of Shanggan, or basically follow the modern pharmacol

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1. Preparation and detection of drugs for treating upper respiratory tract infections

[0033] 1. Preparation of drugs for the treatment of upper respiratory tract infections in capsule form

[0034] The preparation method of the medicine for treating upper respiratory tract infection in capsule dosage form of the present invention includes the following steps:

[0035] 1) Weigh the raw materials: Polygonum cuspidatum 450g, Forsythia suspense 360g, Banlan root 360g, Bupleurum 360g, Patrinia vulgaris 360g, Verbena 360g, Reed root 270g, Licorice 180g.

[0036] 2) Pulverize Polygonum cuspidatum and Radix Isatidis into granules, add 5 times volume of 70% ethanol, heat reflux for extraction for 2.0 hours, filter; collect the medicine residue, add 3 times volume of 70% ethanol to the medicine residue, heat reflux for extraction After 1.0 hour, filter; combine the filtrates obtained from the above two refluxes, recover ethanol and concentrate under reduced pressure (vacuum...

Embodiment 2

[0045] Example 2. Animal Toxicology Test

[0046] 1. Acute toxicity test

[0047] experiment material:

[0048] animal:

[0049] Kunming mice (40), weighing 22.7±1.1g, half female and half male: Sprague-Dawley rats (30), weighing 103.03±11g, half female and half male. All experimental animals and feed were provided by the former Experimental Animal Center of Hunan Medical University. Medical Laboratory Animal Qualification Certificate (Mice Kunming Species) (Yidong Zi No. 20-011), Medical Laboratory Animal Qualification Certificate (Rat SD Strain) (Yidong Zi No. 20-010) number).

[0050] drug:

[0051] The full-component medicine prepared in Example 1, the capsule for treating upper respiratory tract infections is now named as Virus Clear Capsule, and the specification is 0.52 g / capsule, which is equivalent to 2.7 g crude drug. Before the test, peel off the capsule shell and pour out the contents, and prepare a suspension with the required concentration in the following test with ...

Embodiment 3

[0089] Example 3. Pharmacological test

[0090] The full-component medicine prepared in Example 1, the capsule for treating upper respiratory tract infection is now named as Virus Clear Capsule, and the specification is 0.52 g / capsule, which is equivalent to 2.7 g crude drug. Before the test, peel off the capsule shell and pour out the contents, and prepare a suspension with the required concentration in the following test with distilled water.

[0091] 1. In vitro and in vivo antiviral test

[0092] 1. In vitro antiviral test

[0093] 1) Toxicity test on cells

[0094] Dilute the drug (crude drug 5.0g / mL) with MEM eagle medium to 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, and culture Hela cells separately, each 4 culture tubes at one concentration, static culture at 37°C, observe the cytopathic effect (CPE) daily, and report the results after 5 days. The test results show that the drug concentration is ≤17.3mg / mL, the cell growth is normal, and it has no toxic effect on the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Maximum tolerated doseaaaaaaaaaa
Login to view more

Abstract

The medicine for treating upper respiratory tract infection is prepared with the main materials including giant knotweed 4-6 weight portions, forsythia 3-5 weight portions and isatis root 3-5 weight portions, and adjuvant including bupleurum root 3-5 weight portions, patrinia herb3-5 weight portions, European verbena3-5 weight portions, reed rhizome 2-4 weight portions and licorice 1-3 weight portions. The medicine of the present invention can improve the ischemic and anoxic state of local tissue and improve microcirculation, and has obvious curative effect on common cold, acute tonsillitis, acute pharyngolaryngitis, acute parotitis an other upper respiratory tract infection diseases. The medicine has no toxic side effect and low cost.

Description

Technical field [0001] The invention relates to a medicine for treating upper respiratory tract infection and a preparation method thereof, in particular to a medicine for treating upper respiratory tract infection prepared by using Chinese herbal medicine as a raw material and a preparation method thereof. Background technique [0002] Acute upper respiratory tract infection is a very common and frequently-occurring disease in clinical practice, and it is also one of the causes of acute attacks of common chronic diseases. Acute upper respiratory tract infection (acute upper respiratory tract infection) is a general term for acute inflammation of the nasal cavity, pharynx or throat. About 70-80% of acute upper respiratory tract infections are caused by viruses. Bacterial infections can be directly infected or secondary to viral infections. Streptococcus hemolyticus is the most common infection, followed by pneumococcus, Staphylococcus, Haemophilus influenzae, and occasionally Gra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/899A61K36/85A61K36/704A61K36/634A61K36/233A61K9/48A61P11/00
Inventor 张军兵汪平武惠斌
Owner 安徽济人药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap